How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,819 results for

Renin-Angiotensin System

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Renin-angiotensin system drugs

Renin-angiotensin system drugs Renin-angiotensin system drugs: dual ther Renin-angiotensin system drugs: dual therap apy y Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt2 pathways Options for local implementation Options for local implementation Dual therapy with an angiotensin-converting enzyme (ACE) inhibitor plus an angiotensin receptor blocker (ARB) has only a limited place in treatment, specifically in a small minority of people with heart failure. Review (...) heart failure and there was an increased risk of hyperkalaemia, hypotension, and impaired renal function. See the NICE medicines evidence commentary Efficacy and safety of dual blockade of the renin-angiotensin system for more information. UK Medicines Information (UKMi) has also published a medicines question and answers resource on the rationale and evidence for combining ACE inhibitors with ARBs for treating hypertension and for preventing vascular events. Dual therapy has only a limited place

2015 National Institute for Health and Clinical Excellence - Advice

2. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Full Text available with Trip Pro

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19.In this case-population study, we consecutively

2020 Lancet

3. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. Full Text available with Trip Pro

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well studied.We carried out a population-based case-control study in the Lombardy region of Italy. A total of 6272 case patients in whom infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed

2020 NEJM

4. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. Full Text available with Trip Pro

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics

2020 NEJM

5. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Full Text available with Trip Pro

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Metab Syndr Actions . 2020 Jun 27;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Online ahead of print. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis , , , , , , , , , Affiliations Expand Affiliations 1 Faculty of Medicine

2020 EvidenceUpdates

6. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Full Text available with Trip Pro

Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) . Online ahead of print. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis , Affiliations Expand Affiliation 1 Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. PMID: 32767823 PMCID: DOI: Free PMC article Item in Clipboard Review Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta

2020 EvidenceUpdates

7. Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes

Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Article Text

2017 Evidence-Based Medicine

8. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) MD FRCP and Peter Winocour MD FRCP July 2017 Contents Introduction 3 Evidence grades for the recommendations 3 Search strategy 3 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes 5 Recommendations 6 Audit standards 6 Areas that require further research 7 Introduction 7 Hypertension in patients with type 1 diabetes 8 Modulation of the RAAS in patients with type 1 diabetes 9 2 Hypertension management and renin-angiotensin-aldosterone system

2017 Association of British Clinical Diabetologists

9. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 In light of feedback, we have clarified (...) our article on concomitant use of these medicines in heart failure. Published 13 December 2016 From: Therapeutic area: , In February 2016, we published an article about the use of spironolactone and renin-angiotensin system drugs in patients with heart failure. Following publication, we received feedback from a small number of readers and a professional organisation that the article was inconsistent with clinical guidelines. We sought advice from the , who considered that the advice outlined

2017 MHRA Drug Safety Update

10. Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Full Text available with Trip Pro

Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Functional roles of the angiotensin peptides of the renin-angiotensin system (RAS) cascade can be analyzed through their corresponding proteolytic regulatory enzymes aspartyl aminopeptidase (ASAP), aminopeptidase A (APA), aminopeptidase B (APB), aminopeptidase N (APN) and insulin-regulated aminopeptidase (IRAP). These enzyme activities

2018 Biomedicines

11. Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. Full Text available with Trip Pro

Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. We investigate the effects of aerobic exercise training (AET) on the thermogenic response, substrate metabolism and renin angiotensin system (RAS) in the subcutaneous white adipose tissue (SC-WAT) of mice fed cafeteria diet (CAF). Male C57BL/6J mice were assigned into groups CHOW-SED (chow diet, sedentary; n = 10), CHOW-TR (chow diet

2019 PLoS ONE

12. Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands. Full Text available with Trip Pro

Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands. Renin-angiotensin system (RAS) systemically or locally collaborates with tissue homeostasis, growth and development, which has been extensively studied for its pharmacological implications. This study was primarily aimed at finding and characterizing local RAS in rat parotid, sublingual and submandibular glands. It was also hypothesized that vasoactive drugs could affect the expression (...) (ACE and both AT receptors), without affecting morphological alterations, and significantly decreased saliva and total protein secretions. Isoproterenol treatment affected gene expression profiles in parotid (ACE, ACE-2, AT1-a, MAS, AGT), and submandibular (ACE, AT2, AGT) glands, thus promoting acinar hypertrophy in serous acini, without significant changes in salivary flow or total protein content. These drugs affected mainly acini, followed by duct systems and myoepithelial cells, whereas blood

2019 PLoS ONE

13. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. Full Text available with Trip Pro

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. Data on hyperkalemia frequency among chronic kidney disease (CKD) patients receiving renin-angiotensin aldosterone system inhibitors (RAASis) and its impact on subsequent RAASi treatment are limited. This population-based cohort study sought to assess the incidence of clinically significant hyperkalemia among adult CKD patients who were prescribed

2019 PLoS ONE

14. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy Full Text available with Trip Pro

Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested (...) a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired

2018 EvidenceUpdates

15. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. Full Text available with Trip Pro

Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. Renin-angiotensin system inhibitors (RAS) drugs have a proteinuria-reducing effect that could prevent the progression of kidney disease in diabetic patients. Our study aimed to assess the budget impact based on healthcare payer perspective of increasing uptake of RAS

2019 PLoS ONE

16. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial Full Text available with Trip Pro

The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB

2018 EvidenceUpdates

17. Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Full Text available with Trip Pro

Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. In liver cirrhosis, renin-angiotensin system (RAS) activation sustains renal sodium retention and hepatic fibrogenesis. New information has recently enlivened the traditional concept of RAS. For instance, renin and prorenin bind their ubiquitous receptors, resulting in the local production of angiotensin (Ang) II; increased serum calcium and calcimimetic agents (...) , through stimulation of extracellular calcium-sensing receptors (CaSR), blunt renin production and lead to natriuretic effects in human and experimental cirrhosis. Alongside systemic production, there is Ang II tissue production within various organs through RAS enzymes different from angiotensin-converting enzyme (ACE), that is chymase, tissue plasminogen activator and several cathepsins. In experimental cirrhosis, inhibition of chymase leads to natriuretic and hepatic antifibrotic effects, without

2020 Liver International

18. Renin-angiotensin system inhibitors in COVID-19. Full Text available with Trip Pro

Renin-angiotensin system inhibitors in COVID-19. Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater

2020 Cleveland Clinic journal of medicine

19. Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review. (Abstract)

Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review. The renin-angiotensin system (RAS) is one of the oldest and most extensively studied human peptide cascades, well-known for its role in regulating blood pressure. When aldosterone is included, RAAS is involved also in fluid and electrolyte homeostasis. There are two main axes of RAAS: (1) Angiotensin (1-7), angiotensin converting enzyme 2 and Mas receptor (ACE2-Ang(1-7)-MasR), (2 (...) , such as the one present in the vascular endothelium, are responsible for long-term regional changes. A local RAAS and its components have been detected in many structures of the human eye. This review focuses on the local ocular RAAS in the anterior part of the eye, its possible role in aqueous humour dynamics and intraocular pressure as well as RAAS as a potential target for anti-glaucomatous drugs.KEY MESSAGESComponents of renin-angiotensin-aldosterone system have been detected in different structures

2020 Annals of medicine

20. Bi-allelic mutations in renin-angiotensin system genes, associated with renal tubular dysgenesis, can also present as a progressive chronic kidney disease. (Abstract)

Bi-allelic mutations in renin-angiotensin system genes, associated with renal tubular dysgenesis, can also present as a progressive chronic kidney disease. Bi-allelic loss of function variations in genes encoding proteins of the renin-angiotensin system (AGT, ACE, REN, AGTR1) are associated with autosomal recessive renal tubular dysgenesis, a severe disease characterized by the absence of differentiated proximal tubules leading to fetal anuria and neonatal end-stage renal disease.We identified

2020 Pediatric Nephrology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>